Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $12.00 - $14.00
Current IPO price range

Company Description

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.

For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated.

Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system - the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuvants, and other immunomodulators will more efficiently educate, activate, and amplify critical immune cells, resulting in induction and persistence of potent adaptive immunity required to treat many diseases.

Our lead product candidate, ELI-002, is being developed to treat cancers driven by KRAS, a mutation found in approximately 25% of tumors. We are conducting a Phase 1/2 clinical trial of ELI-002 (AMPLIFY-201) and anticipate initial safety, dose escalation, and correlative biomarker data in the first half of 2022.

We are also evaluating the potential use of ELI-004, our universal AMP-modified CpG adjuvant, and a component of ELI-002, in conjunction with other disease-specific antigens, to treat or prevent additional diseases.

Elicio Therapeutics, Inc.
Country United States
Founded 2011
Industry Pharmaceutical Preparations
Sector Biotechnology
Employees 22
CEO Robert Connelly

Contact Details

Address:
One Kendall Square, Building 1400 West, Suite 14303
Cambridge, MA 02139
United States
Phone (857) 209-0050
Website elicio.com

Stock Details

Ticker Symbol ELTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1555192

Key Executives

Name Position
Robert Connelly Chief Executive Officer, President and Director
Daniel Geffken Interim Chief Financial Officer and Director
Christopher Haqq, M.D., Ph.D. Executive Vice President, Head of Research and Development and Chief Medical Officer
Annette Matthies, Ph.D. Chief Business Officer
Julian Adams, Ph.D. Chairman and Director
Carol Ashe Director
Ofer Gonen Director
Daphne Karydas Director

Latest SEC Filings

Date Type Title
May 27, 2022 D Notice of Exempt Offering of Securities
Nov 18, 2021 D/A Notice of Exempt Offering of Securities
Nov 12, 2021 D/A Notice of Exempt Offering of Securities
Oct 19, 2021 D Notice of Exempt Offering of Securities
Jul 13, 2021 S-1/A General form for registration of securities under the Securities Act of 1933
Jun 29, 2021 S-1/A General form for registration of securities under the Securities Act of 1933
Jun 28, 2021 S-1 General form for registration of securities under the Securities Act of 1933
Jun 9, 2021 DRS/A Draft Registration Statement
Apr 23, 2021 DRS Draft Registration Statement
Jul 15, 2020 D Notice of Exempt Offering of Securities